Crystalline Form of Cabazitaxel and Process for Preparing the Same
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,309,210 | Crystalline Form of Cabazitaxel and Process for Preparing the Same In force · High confidence | Aventis Pharma S.A. | In force | High confidence | ||
| Application 15/092,919 | Crystalline Form of Cabazitaxel and Process for Preparing the Same Abandoned Abandoned Dec 10, 2018 | Sanofi | Abandoned | Abandoned Dec 10, 2018 |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Aventis Pharma S.A..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.